REGENXBIO Q4 2025 Earnings – AlphaStreet News
[ad_1] Financial Performance and Liquidity Operating Expenses Pipeline and Operational Developments The company advanced its Duchenne muscular dystrophy program, reporting that patients treated with the pivotal dose of RGX-202 demonstrated an average improvement of 7.4 points on the North Star…







